ResMed (RMD) Stock Price, News & Analysis

Company Overview

ResMed Inc. is a medical equipment and software company that develops products and services for the diagnosis and treatment of sleep-disordered breathing and other respiratory conditions. Its offerings include continuous positive airway pressure (CPAP) and other positive airway pressure devices, masks, ventilation systems, oxygen-related solutions, and connected health technologies.

The company also provides cloud-based software and digital health platforms that help clinicians, home medical equipment providers, and patients monitor therapy, manage equipment, and support adherence to treatment. ResMed serves patients and healthcare organizations through a broad international commercial and distribution network.

ResMed was founded in 1989 and has roots in Australia, where it was established to commercialize technology for treating obstructive sleep apnea. The company is headquartered in San Diego, California, and its shares trade on the New York Stock Exchange and the Australian Securities Exchange. ResMed is led by Chief Executive Officer Mick Farrell.

Key Stats

• Today's Range: $223.16 to $227.90
• 50-Day Range: $191.83 to $240.47
• 52-Week Range: $180.26 to $284.87
• Volume: 280,900 shs
• Average Volume: 1.32 million shs
• Market Capitalization: $32.38 billion
• P/E Ratio: 21.52
• Dividend Yield: 1.18%
• Price Target: $241.69
• Consensus Rating: Hold

ResMed Stock Analysis - MarketRank™

ResMed scored higher than 81% of companies evaluated by MarketBeat, and ranked 90th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Hold

Consensus Rating

ResMed has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on no strong buy ratings, 7 buy ratings, 9 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for ResMed is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

ResMed has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 8.90%

Earnings Growth

Earnings for ResMed are expected to grow by 8.90% in the coming year, from $12.02 to $13.09 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ResMed is 21.55, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.12.

Price to Earnings Ratio vs. Sector

The P/E ratio of ResMed is 21.55, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.41.

Price to Earnings Growth Ratio

ResMed has a PEG Ratio of 1.42. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

ResMed has a P/B Ratio of 4.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.12% of the float of ResMed has been sold short.

Short Interest Ratio / Days to Cover

ResMed has a short interest ratio ("days to cover") of 8.94.

Change versus previous month

Short interest in ResMed has recently increased by 2.17%, indicating that investor sentiment is decreasing.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Yield

ResMed pays a meaningful dividend of 1.17%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

ResMed has been increasing its dividend for 13 years.

Dividend Coverage

The dividend payout ratio of ResMed is 25.31%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, ResMed will have a dividend payout ratio of 20.17% next year. This indicates that ResMed will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.83

News Sentiment

ResMed has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for ResMed this week, compared to 7 articles on an average week.

Search Interest

Only 6 people have searched for RMD on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added ResMed to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ResMed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,255,268.00 in company stock.

Percentage Held by Insiders

0.65% of the stock of ResMed is held by insiders.

Percentage Held by Institutions

54.98% of the stock of ResMed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Record date for 9/24 Dividend: 8/20/2026
• Ex-Dividend for 9/24 Dividend: 8/20/2026
• Today: 9/22/2026
• Dividend Payable: 9/24/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:RMD
• CIK: 943819
• Web: www.resmed.com
• Phone: (858) 836-5000
• Fax: 858-836-5501
• Employees: 11,370
• Year Founded: 1994

Price Target and Rating

• Average Price Target for ResMed: $241.69
• High Price Target: $300.00
• Low Price Target: $213.00
• Potential Upside/Downside: +7.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.44
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): $10.43
• Trailing P/E Ratio: 21.52
• Forward P/E Ratio: 18.68
• P/E Growth: 1.42
• Net Income: $1.52 billion
• Net Margins: 26.94%
• Pretax Margin: 33.95%
• Return on Equity: 25.58%
• Return on Assets: 18.89%

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 3.10
• Quick Ratio: 2.42

Sales & Book Value

• Annual Sales: $5.65 billion
• Price / Sales: 5.73
• Cash Flow: $12.90 per share
• Price / Cash Flow: 17.40
• Book Value: $45.40 per share
• Price / Book: 4.94

Miscellaneous

• Outstanding Shares: 144,250,000
• Free Float: 143,314,000
• Market Cap: $32.38 billion
• Optionable: Optionable
• Beta: 0.77